Hongyu Ni, MD, PhD


Associate Professor of Clinical Pathology
Department of Pathology
University of Illinois at Chicago
840 South Wood Street, Chicago, Illinois 60612, USA

Biography

Dr. Ni is board certified in anatomic pathology, clinical pathology and hematopathology. He is currently an associate professor of clinical pathology and the director of hematopathology at the University of Illinois at Chicago Hospital and Health Science System. He received his MD. Degree from the West China University of Medical Sciences, where he also completed his medical training in hematology. Dr. Ni received his Master degree from Queen’s University at Kingston and Ph.D. degree from McMaster University in Canada. He completed his residency training in anatomic and clinical pathology as well as fellowship training in hematopathology at Loyola University Medical Center in Maywood, Illinois.

Research Interest

Research interests include: Pathogenesis of myeloproliferative neoplasms and myelodysplastic syndromes.

Scientific Activities

HONORS AND AWARDS

2013: Distinguished Alumnus, Department of Pathology, Loyola University Medical Center, Maywood, Illinois
1993-1994-1995: Ontario graduate student scholarship, McMaster University, Hamilton, Ontario, Canada
1988-1989-1990: Dean’s Award, Queen’s University, Kingston, Ontario, Canada
1980-1982: Excellent student awards, West China University of Medical Sciences, Chengdu, Sichuan, China

Publications

PUBLICATIONS (peer reviewed)

1. Pan F., Wingo TS., Zhao Z., Gao R., Makishima H., Qu G., Lin L., Yu M., Ortga JR., Wang J., Nazha A., Chen L., Yao B., Liu C., Chen S., Weeks O., Ni H., Phillips BL., Huang S., Wang J., He C., Li GM., Radivoyevitch T., Aifantis I., Maciejewski JP., Yang FC., Jin P., Xu M: Tet2 loss leads to hypermutagenicity in hematopoietic stem/progenitor cells. Nature Communications 8:15102, 2017.
2. Zhao Z, Chen S, Zhu X, Pan F, Li R, Zhou Y, Yuan W, Ni H, Yang FC, Xu M.: The catalytic activity of TET2 is essential for its myeloid malignancy-suppressive function in hematopoietic stem/progenitor cells. Leukemia 30:1784-1788, 2016.
3. Liu Y., Yan Y., Webster C., Shao L., Lensing S., Ni H., Feng W., Colorado N., Rathak R., Zhou D., Xiang Z., Hauer-Jensen M., Li S., Emanuel P.: Timing of the loss of PTEN protein determine disease severity in a mouse model of myeloid malignancy. Blood127; 1912-1922, 2016.
4. Zhao Z., Meelad D., Li L., Lihn N., Wang J., Pan F., Chen S., Weeks O., Ni H., Jaenisch R., Yang F., Xu M.: Combined loss of Tet1 and Tet2 promotes B-cell, but not myeloid malignancies in mice. Cell Rep. 13:1692-704, 2015.
5. Wang J., Li Z., He Y., Craig S., Pan F., Chen S., Rhodes S., Nguyen L., Yang X., Zhou J., Cai C., Ni H., Jin P., Xu M., Yang F.: Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood 123:541-553, 2014.
6. Imai M., Jiang J., Wu Z., Dabbas B., Ni H.: CD20-positive T-cell lymphoma involving bone marrow: Report of four cases. J Hematopathol 6:201-205, 2013.
7. Migliaccio AR., Martelli F., Verrucci M, Migliaccio G., Vannucchi A.M. Ni H., Jiang Y., Nakamoto B., Papayannopoulou T. Hoffman R.: Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata (low) mouse model of the disease. Exp. Hematol 36:158-171, 2008.
8. Ozpuyan F., Meywe P.,Ni H., Al-Masri H., Alkan S.: Bortezomib induces apoptosis in T-cell prolymphocytic leukaemia (T-PLL). Leuk. Lymphoma 48:2247-2250, 2007.
9. Gaitonde S.,Vidanovic V. Ni H.: Concomitant and fatal HHV-8+ multicentric Castleman’s disease and Kaposi’s sarcoma in the same lymph node of an HIV- liver transplant patient. Histopathology 50:954-8, 2007.
10. Compos M. Younger K., Alvarez H., Ni H., Gaitonde S.: Peripheral T-cell lymphoma with gamma/delta phenotype clinically present with splenomegaly. Histopathology 49:241-7, 2007.
11. Ni H., Barosi G., Hoffman R.: Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis. Am. J. Clin. Pathol 126:241-7, 2006.
12. Ni H. Barosi G., Rondelli D., Hoffman R.: Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis. Am. J. Clin. Pathol 123:836-839, 2005.
13. Xu M., Bruno E., Chao J., Ni H., Lindgren V., Nunez R., Mahmud N., Finazzi G., Fruchtman S., Popat U., Liu E., Prchal J., Rondelli D., Barosi G., and Hoffman R.: The constitutive mobilization of bone marrow repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 105:1699-1705, 2005.
14. Buonamici S., Li D., Chi Y., Chakraborty S., Zhao R., Senyuk V., Crispino J., Nunez R., Larry B., Ni H., Saunthararajah Y., Nucifora G.: Forced expression of EVI1 induces myelodysplastic syndrome in mouse. J Clin Invest114:713-719, 2004.
15. Jani J., Gaitonde S., Saunthararajah Y., Ni H.: A 68-year old man with thrombocytosis and ringed sideroblasts.Arch Pathol Lab Med 128:815-816, 2004.
16. Ni H., Ergin M., Tibudan S.S., Denning M.F., Izban K.F., Alkan S.: Protein kinase C-Delta is commonly expressed in multiple myeloma cells and its downregulation by Rottlerin causes apoptosis. Br J Haematol 121:849-856, 2003.
17. Ni H., Ergin M., Huang Q. Qin J-Z. Amin H., Martinez R., Saeed S., Barton K., Alkan S.: Analysis of expression of NF-B in multiple myeloma: Down-regulation of NF-B induces apoptosis. Br J Haematol 115:279-286, 2001.
18. Izban K., Ergin M., Huang Q., Qin J., Schnitzer R.L., Ni H., Nickoloff B.J., Alkan S.: Characterization of NF-B expression in Hodgkin’s disease: Inhibition of constitutively expressed NF-B results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol 14:297-310, 2001.
19. Hartman G., Ni H., Pickeman J.: Acinar cell carcinoma of the pancreas. Arch Pathol Lab Med 125:1127-1128, 2001.
20. Ni H., Blajchman M.A, Ananthanarayanan V.S., Smith I.J. Sheffield W.P.: Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. Thromb Res 99:407-415, 2000.
21. Ni H., Waye J.S., Sheffield W.P., Eng B., Blajchman M.A.: Genetic linkage studies in antithrombin deficient kindreds using a highly polymorphic trinucleotide short tandem repeat (STR) within the human antithrombin gene. Am J Hematol 46:107-111, 1994.
22. Ni H., Waye J.S., Austin R. Calverley D., Eng B., Sheffield W.P., Blajchman M.A.: Characterization of a highly polymorphic trinucleotide short tandem repeat (STR) within the human antithrombin (AT) gene. Thromb Res 74(3):303-307, 1994.
23. Waye J.S., Eng B., Ni H., Blajchman M.A., Carmody G.: Trinucleotide repeat polymorphism within the human antithrombin gene (AT3): allele frequency data for three population groups. Mol Cell Probes 8:149-154, 1994.
24. Ni H., Giles A.R.: Normalization of the haemostatic plug of dogs with Haemophilia A (Factor VIII deficiency) following the infusion of a combination of factor Xa and phosphatidylcholine/phosphatidylserine vesicles. Thromb Haemostas 67:264-271, 1992.
25. Teitel J.M., Ni H., Freedman J.J., Garvey M.B.: The endothelial cell and the factor VIII bypassing activity of prothrombin complex concentrate. Thromb Haemostas 60:226-229, 1988.
26. Ni H., Deng C., Ruan H.: Alteration of platelet function and ultrastructure in myeloproliferative disorders and its clinical significance. Journal of West China University of Medical Sciences 19:312-316, 1988.

MANUSCRIPTS SUBMITTED

1. Pan F., Wingo T., Zhao Z., Street C., Yu M., Qu G., Li L., Faiola F., Li L., Nguyen L., Wang J., Makishima H., Chen S., Weeks O., Liu S., Maciejewski J., Ni H., Wang J., He C., Li G., Lannis A., Yang F., Jin P., Xu M.: TET2 protects stability through interaction with MSH6. Nature (submitted for publication, under revision) 2015.

REVIEW ARTICLES

1. Ni H.: Chronic Leukemias and Lymphomas: Biology, Pathophysiology, and Clinical Management (book review). Arch Pathol Lab Med 127: 1055–1055, 2003.
2. Ni H., Blajchman M.A.: Understanding the Polymerase Chain Reaction. Transfusion Medicine Reviews. 8:242-252, 1994.